ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1722

Exploring How Patients with Rheumatoid Arthritis Use a Methotrexate Decision Aid for Making Treatment Choices

Linda C. Li1, Anne F. Townsend2, Paul M. Adam3, Catherine L. Backman4, Sydney Brooks5, Gwen A. Ellert6, Allyson Jones7, Otto Kamensek8, Cheryl Koehn9, Diane Lacaille8, Jenny Leese2, Colleen Maloney8, Elaine Yacyshyn10, Charlene Yousefi8 and Dawn Stacey11, 1Department of Physical Therapy, University of British Columbia, Vancouver, BC, Canada, 2Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, 3Rheumatology Liaison, Mary Pack Arthritis Centre, Vancouver, BC, Canada, 4Occupational Science & Occupational Therapy, The University of British Columbia, Vancouver, BC, Canada, 5The Arthritis Society, Ontario Division, Toronto, ON, Canada, 6Health Education, Trelle Enterprises Inc, Vancouver, BC, Canada, 7Department of Physical Therapy, University of Alberta, Edmonton, AB, Canada, 8Arthritis Research Centre of Canada, Vancouver, BC, Canada, 9Arthritis Consumer Experts, Vancouver, BC, Canada, 10562 Heritage Med Rsch Ctr, University of Alberta, Edmonton, AB, Canada, 11School of Nursing, University of Ottawa, Ottawa, ON, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Education, methotrexate (MTX), patient, patient preferences, rheumatoid arthritis (RA) and treatment options

  • Tweet
  • Email
  • Print
Session Information

Title: Care of Patients With Rheumatoid Arthritis

Session Type: Abstract Submissions (ARHP)

Background/Purpose: For patients with rheumatoid arthritis (RA), making treatment decisions can be overwhelming. The literature describes a sense of ambivalence among patients with chronic diseases toward medication use. For people considering methotrexate (MTX) for RA, we have developed a web-based decision aid called ANSWER. It consists of six animated patient stories and narrated information on the evidence of MTX for RA, and questionnaires to clarify individuals’ treatment preferences. ANSWER asks patients to consider two options: 1) take MTX as prescribed, or 2) discuss options other than MTX with their doctors. At the end of the program, it produces a one-page summary with the patient’s preferred treatment choices and questions, which can be presented to the doctor at the next medical visit. The current study aimed to understand patients’ experiences with this new MTX decision aid.

Methods:   This qualitative study was conducted within a proof-of-concept study on the ANSWER. Individuals were recruited from rheumatologists’ clinics, patient groups and social networking sites. Eligible participants were those who had been diagnosed with RA, had been prescribed MTX but were unsure about starting it, and with access to the internet. Of the 30 participants enrolled, 11 were randomly selected to participate in an in-depth telephone interview on 3 broad topics: 1) their experience with the ANSWER, 2) their use of the Internet for health information, and 3) their views on disseminating the ANSWER to others with RA. We conducted thematic content analysis to understand their experiences.

Results:    Eight women and 3 men, aged 31 to 65 years, were interviewed. All participants were MTX naïve at the time of enrolment, with disease duration from less than 1 week to 16 years. Of the 11 participants, 7 were able to make a decision after using ANSWER, and 4 remained unsure. Our analysis identified 3 main themes: 1) Seeking confirmation: regardless of their prior level of knowledge on RA and MTX, participants constantly compared what they learnt from ANSWER and sought confirmation with their own knowledge, even some of which was inaccurate. 2) Amplifying reluctance: while using ANSWER, participants’ doubts about using MTX increased when they encountered information that did not align with their own experience with the disease. 3) Clarifying thoughts: By completing the ANSWER’s preference clarification questionnaire, some participants were able to reach the ‘best option’ for them. Several participants commented that ANSWER legitimized the practice of asking questions during medical visits and advocating for themselves.

Conclusion:   Our preliminary findings highlight the power of patients’ prior knowledge and experiences with RA on how they approach the information presented in a decision aid. This suggests that decision aids should address myths about RA, in addition to presenting the evidence of treatment options. Moreover, as the ANSWER serves only to initiate the discussion between patients and their doctors about MTX, further strategies are needed to support ongoing patient-doctor communication during medical visits.


Disclosure:

L. C. Li,
None;

A. F. Townsend,
None;

P. M. Adam,
None;

C. L. Backman,
None;

S. Brooks,
None;

G. A. Ellert,
None;

A. Jones,
None;

O. Kamensek,
None;

C. Koehn,
None;

D. Lacaille,
None;

J. Leese,
None;

C. Maloney,
None;

E. Yacyshyn,
None;

C. Yousefi,
None;

D. Stacey,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/exploring-how-patients-with-rheumatoid-arthritis-use-a-methotrexate-decision-aid-for-making-treatment-choices/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology